Raheleh Rahbari

Has grant

Group Leader

Wellcome Sanger Institute
Country flagUnited Kingdom

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Open

Harnessing Comparative Genomics to Uncover the Principles of Somatic Evolution and Healthy Ageing

Open Date: 2026-05-01

Close Date: 2034-04-30

Positions (1)

Publisher
source

Raheleh Rahbari

University Name
.

Wellcome Sanger Institute

Wellcome Sanger Institute is recruiting a Postdoctoral Fellow / Senior Postdoctoral Fellow to join the Somatic Genomics Programme in the group led by Raheleh Rahbari . The project sits at the interface of genomics , computation , and evolutionary biology , with a strong emphasis on human somatic evolution and the analysis of large-scale sequencing data . Research themes include how mutations accumulate across tissues, how environmental and clinical exposures such as chemotherapy shape somatic mutation patterns, and what these processes mean for disease risk and inheritance . The post is well suited to candidates interested in quantitative analysis, computational genomics, and independent research in a collaborative environment. This is a postdoctoral opening rather than a scholarship. The post explicitly seeks applicants with strong quantitative/computational skills. No funding, stipend, or waiver information is stated in the post excerpt. The application deadline is 6 May 2026 . Apply through the linked job posting on the Wellcome Sanger Institute recruitment portal.

7 months ago

Articles (6)

Most of the risk factors associated with chronic and complex diseases, such as cancer, stem from exogenous and endogenous exposures experienced throughout an individual’s life, collectively known as the exposome. These exposures can modify DNA, which can subsequently lead to the somatic mutations found in all normal and tumor tissues. Understanding the precise origins of specific somatic mutations has been challenging due to multitude of DNA adducts (i.e. the DNA adductome) and their diverse positions within the genome. Thus far, this limitation has prevented researchers from precisely linking exposures to DNA adducts and DNA adducts to subsequent mutational outcomes. Indeed, many common mutations observed in human cancers appear to originate from error-prone endogenous processes. Consequently, it remains unclear whether these mutations result from exposure-induced DNA adducts, or arise indirectly from endogenous processes or are a combination of both. In this review, we summarize approaches that aim to bridge our understanding of the mechanism by which exposure leads to DNA damage and then to mutation and highlight some of the remaining challenges and shortcomings to fully supporting this paradigm. We emphasize the need to integrate cellular DNA adductomics, long read-based mapping, single-molecule duplex sequencing of native DNA molecules and advanced computational analysis. This proposed holistic approach aims to unveil the causal connections between key DNA modifications and the mutational landscape, whether they originate from external exposures, internal processes or a combination of both, thereby addressing key questions in cancer biology.

Year:

2025

In renewing tissues, mutations conferring selective advantage may result in clonal expansions 1–4 . In contrast to somatic tissues, mutations driving clonal expansions in spermatogonia (CES) are also transmitted to the next generation. This results in an effective increase of de novo mutation rate for CES drivers 5–8 . CES was originally discovered through extreme recurrence of de novo mutations causing Apert syndrome 5 . Here, we develop a systematic approach to discover CES drivers as hotspots of human de novo mutation. Our analysis of 54,715 trios ascertained for rare conditions 9–13 , 6,065 control trios 12,14–19 and population variation from 807,162 mostly healthy individuals 20 identifies genes manifesting rates of de novo mutations inconsistent with plausible models of disease ascertainment. We propose 23 genes hypermutable at loss-of-function (LoF) sites as candidate CES drivers. An extra 17 genes feature hypermutable missense mutations at individual positions, suggesting CES acting through gain of function. CES increases the average mutation rate roughly 17-fold for LoF genes in both control trios and sperm and roughly 500-fold for pooled gain-of-function sites in sperm 21 . Positive selection in the male germline elevates the prevalence of genetic disorders and increases polymorphism levels, masking the effect of negative selection in human populations. Despite the excess of mutations in disease cohorts for 19 LoF CES driver candidates, only 9 show clear evidence of disease causality 22 , suggesting that CES may lead to false-positive disease associations.

Year:

2025

De novo germline mutation is an important factor in the evolution of allelic diversity and disease predisposition in a population. Here, we study the influence of genetically-inferred ancestry and environmental factors on de novo mutation rates and spectra. Using a genetically diverse sample of ~10 K whole-genome sequenced trios, one of the largest de novo mutation catalogues to date, we found that genetically-inferred ancestry is associated with modest but significant changes in both germline mutation rate and spectra across continental populations. These effects may be due to genetic or environmental factors correlated with ancestry. We find epidemiological evidence that cigarette smoking is significantly associated with increased de novo mutation rate, but it does not mediate the observed ancestry effects. Investigation of several other potential mutagenic factors using Mendelian randomisation showed no consistent effects, except for age at menopause, where factors increasing this corresponded to a reduction in de novo mutation rate. Overall, our study sheds light on factors influencing de novo mutation rates and spectra.

Year:

2025

In renewing tissues, mutations conferring selective advantage may result in clonal expansions 1–4 . In contrast to somatic tissues, mutations driving clonal expansions in spermatogonia (CES) are also transmitted to the next generation. This results in an effective increase of de novo mutation rate for CES drivers 5–8 . CES was originally discovered through extreme recurrence of de novo mutations causing Apert syndrome 5 . Here, we develop a systematic approach to discover CES drivers as hotspots of human de novo mutation. Our analysis of 54,715 trios ascertained for rare conditions 9–13, 6,065 control trios12,14–19, and population variation from 807,162 mostly healthy individuals 20 identifies genes manifesting rates of de novo mutations inconsistent with plausible models of disease ascertainment. We propose 23 genes hypermutable at loss-of-function (LoF) sites as candidate CES drivers. An additional 17 genes feature hypermutable missense mutations at individual positions, suggesting CES acting through gain-of-function (GoF). CES increases the average mutation rate ∼17-fold for LoF genes in both control trios and sperm and ∼500-fold for pooled GoF sites in sperm. Positive selection in the male germline elevates the prevalence of genetic disorders and increases polymorphism levels, masking the effect of negative selection in human populations. Despite the excess of mutations in disease cohorts for 19 LoF CES driver candidates, only 9 show clear evidence of disease causality 21 , suggesting that CES may lead to false-positive disease associations.

Year:

2025

Mutations that occur in the cell lineages of sperm or eggs can be transmitted to offspring. In humans, positive selection of driver mutations during spermatogenesis is known to increase the birth prevalence of certain developmental disorders. Until recently, characterising the extent of this selection in sperm has been limited by the error rates of sequencing technologies. Using the duplex sequencing method NanoSeq, we sequenced 81 bulk sperm samples from individuals aged 24 to 75 years. Our findings revealed a linear accumulation of 1.67 (95% CI = 1.41-1.92) mutations per year per haploid genome, driven by two mutational signatures associated with human ageing. Deep targeted and exome NanoSeq of sperm samples identified over 35,000 germline coding mutations. We detected 40 genes (31 novel) under significant positive selection in the male germline, implicating both activating and loss-of-function mechanisms and diverse cellular pathways. Most positively selected genes are associated with developmental or cancer predisposition disorders in children, while four genes that exhibit elevated frequencies of protein-truncating variants in healthy populations. We find that positive selection during spermatogenesis drives a 2-3 fold elevated risk of known disease-causing mutations in sperm, resulting in 3-5% of sperm from middle-aged to elderly individuals carrying a pathogenic mutation across the exome. These findings shed light on the dynamics of germline mutations and highlight a broader increased disease risk for children born to fathers of advanced age than previously appreciated.

Year:

2024

Complex de novo structural variants (dnSVs) are crucial genetic factors in rare disorders, yet their prevalence and characteristics in rare disorders remain poorly understood. Here, we conducted a comprehensive analysis of whole-genome sequencing data of 12,568 families, including 13,698 offspring with rare diseases, as part of the UK 100,000 Genomes Project. We identified 1,872 dnSVs, constituting the largest dnSV dataset reported to date. Complex dnSVs (n=158; 8.4%) emerged as the third most common type of SV, following simple deletions and duplications. We classified 65% of these complex dnSVs into 11 subtypes, based on the classification established through the analysis of cancer whole genomes. 1.4% of probands with neurodevelopmental disorders harbour at least one complex dnSV, a rate two times higher than previously reported. Intriguingly, 12% of exon-disrupting pathogenic dnSVs and 22% of de novo deletions or duplications previously identified by array-based or exome-seq methods were found to be complex dnSVs. This study highlights the importance of complex dnSVs in rare disorders and demonstrates the necessity of careful genomic analysis to avoid overlooking these variants.

Year:

2024

Collaborators (12)

Marcus Cooke

Professor

University of South Florida

UNITED STATES
View details

Vladimir Seplyarskiy

Assistant Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details

Intawat Nookaew

Pro

University of Arkansas for Medical Sciences

UNITED STATES
View details

Gunnar Boysen

Professor - tenured

University of Arkansas for Medical Sciences

UNITED STATES
View details

Evan Koch

Assistant Professor

Yale University

UNITED STATES
View details

David Ussery

Professor of Genomics

Oklahoma State University

UNITED STATES
View details

Ludmil Alexandrov

Professor

University of California, San Diego

UNITED STATES
View details

Matthew Hurles

Wellcome Sanger Institute

UNITED KINGDOM
View details

Peter Campbell

Wellcome Sanger Institute

UNITED KINGDOM
View details

Shamil Sunyaev

Professor

Harvard University

UNITED STATES
View details

Isidro Cortes Ciriano

Research Group Leader

European Bioinformatics Institute

UNITED KINGDOM
View details

Aylwyn Scally

Group leader

University of Cambridge

UNITED KINGDOM
View details